ANGLE Gelecekteki Büyüme

Future kriter kontrolleri 2/6

ANGLE kazanç ve gelirinin sırasıyla yıllık 55.3% ve 51.5% oranında artması tahmin edilirken, EPS'nin yıllık 55.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

55.3%

Kazanç büyüme oranı

55.5%

EPS büyüme oranı

Medical Equipment kazanç büyümesi	22.5%
Gelir büyüme oranı	51.5%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	21 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

AIM:AGL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	36	-6	N/A	-6	2
12/31/2025	17	-14	-10	-11	2
12/31/2024	8	-16	-10	-12	2
6/30/2024	2	-18	-13	-12	N/A
3/31/2024	2	-19	-14	-13	N/A
12/31/2023	2	-20	-15	-14	N/A
9/30/2023	2	-21	-16	-15	N/A
6/30/2023	2	-22	-16	-15	N/A
3/31/2023	1	-22	-17	-16	N/A
12/31/2022	1	-22	-18	-16	N/A
9/30/2022	1	-19	-19	-17	N/A
6/30/2022	1	-17	-19	-18	N/A
3/31/2022	1	-16	-18	-16	N/A
12/31/2021	1	-15	-16	-14	N/A
9/30/2021	1	-15	-13	-12	N/A
6/30/2021	1	-16	-11	-10	N/A
3/31/2021	1	-14	-10	-9	N/A
12/31/2020	1	-12	-8	-8	N/A
6/30/2020	1	-10	-14	-15	N/A
3/31/2020	1	-11	-14	-14	N/A
12/31/2019	1	-11	-13	-13	N/A
10/31/2019	1	-10	-11	-9	N/A
7/31/2019	1	-9	-10	-8	N/A
4/30/2019	1	-9	-9	-7	N/A
1/31/2019	1	-9	-9	-7	N/A
10/31/2018	1	-8	-9	-7	N/A
7/31/2018	1	-8	-9	-7	N/A
4/30/2018	1	-8	N/A	-7	N/A
10/31/2017	0	-7	N/A	-8	N/A
7/31/2017	0	-7	N/A	-8	N/A
4/30/2017	0	-7	N/A	-7	N/A
10/31/2016	1	-5	N/A	-5	N/A
7/31/2016	0	-5	N/A	-5	N/A
4/30/2016	0	-5	N/A	-4	N/A
1/31/2016	0	-5	N/A	-4	N/A
10/31/2015	N/A	-4	N/A	-4	N/A
7/31/2015	N/A	-4	N/A	-4	N/A
4/30/2015	N/A	-4	N/A	-3	N/A
10/31/2014	-1	-3	N/A	-3	N/A
7/31/2014	0	-3	N/A	-2	N/A
4/30/2014	N/A	-2	N/A	-2	N/A
1/31/2014	2	-1	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AGL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: AGL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: AGL önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: AGL şirketinin gelirinin (yıllık 51.5% ) UK pazarından (yıllık 3.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: AGL şirketinin gelirinin (yıllık 51.5% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AGL 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

ANGLE Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

ANGLE plc Provides Revenue Guidance for the First Half of 2024

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

ANGLE plc Provides Earnings Guidance for the Year 2023

Price target decreased by 35% to UK£0.94

Recent updates

Angle plc Announces Parsortix Based PD-L1 Assay Showcased at AACR

New major risk - Share price stability

Angle plc PLC Announces Parsortix enriched CTC & ctDNA in NSCLC Patients

First half 2024 earnings released: UK£0.029 loss per share (vs UK£0.038 loss in 1H 2023)

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

New minor risk - Financial data availability

ANGLE plc to Report First Half, 2024 Results on Sep 26, 2024

Angle plc Announces the Publication of One of the Company's Clinical Studies That Was Submitted to the FDA for De Novo Regulatory Clearance of the Parsortix PC1 System

New minor risk - Shareholder dilution

Full year 2023 earnings released: UK£0.077 loss per share (vs UK£0.088 loss in FY 2022)

ANGLE plc Provides Revenue Guidance for the First Half of 2024

ANGLE plc to Report Q4, 2023 Results on Jun 07, 2024

ANGLE plc Announces Publication of Study Using the Parsortix System

ANGLE plc, Annual General Meeting, Jun 26, 2024

We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate

Consensus revenue estimates decrease by 17%

Consensus revenue estimates decrease by 17%

Price target increased by 15% to UK£1.09

Angle plc Announces Use of Parsortix System in Pre-Clinical Model Unlocks Opportunities for Drug Discovery

ANGLE plc Launches Portrait+ CTC Kit At SABCS

Will ANGLE (LON:AGL) Spend Its Cash Wisely?

ANGLE plc Provides Earnings Guidance for the Year 2023

ANGLE plc Announces the Launch of Its Portrait® PD-L1 Test for the Evaluation of PD-L1 Protein Expression on CTCs Following Extensive Development and Optimisation

First half 2023 earnings released: UK£0.038 loss per share (vs UK£0.039 loss in 1H 2022)

Angle plc Announces the Launch of Its Portrait™ Flex Ctc Assay

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

ANGLE plc Announces Senior Management Appointments

ANGLE plc Announces Board Changes

Price target decreased by 35% to UK£0.94

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully

ANGLE plc Announces Appointment of Joseph (Joe) Eid as Non-Executive Director

Insufficient new directors

ANGLE plc to Report Fiscal Year 2022 Results on Jun 02, 2023

ANGLE plc Announces Appointment of Juliet Thompson as Non-Executive Director

ANGLE plc Announces the Publication of Results from A Multi-Centre Clinical Study

Angle plc Announces It Presented Results from A Proof of Concept Study At the International Society of Liquid Biopsy Meeting in Miami, Florida

ANGLE plc Announces Streamlining of Operations to Increase Cash Runway

First half 2022 earnings: EPS and revenues miss analyst expectations

ANGLE plc Announces Positive Headline Results from Ovarian Study

ANGLE plc Announces Study Using Parsortix in Head and Neck Cancer

ANGLE plc Announces the Publication of Results from A Clinical Study Undertaken in Partnership with the Wilmot Cancer Institute, University of Rochester, NY, US

Price target increased to UK£2.16

Angle plc Announces New Study Highlights Use of Parsortix System to Enable Cancer Cell Dna Analysis in Non-Small Cell Lung Cancer

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

ANGLE plc Announces Ground-Breaking Research by the World-Class Team at the Molecular Oncology Laboratory at the Swiss Federal Institute of Technology Zurich, Switzerland

Angle plc Announces Results of Work Undertaken in Advanced Non-Small Cell Lung Cancer (NSCLC) and Sarcoma Patients

Angle plc Receives FDA Clearance for Parsortix

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target increased to UK£1.85

Insufficient new directors

ANGLE plc, Annual General Meeting, Jun 29, 2022

ANGLE plc to Report Fiscal Year 2021 Results on Apr 28, 2022

Angle Announces Parsortix System Shows Potential for Providing Rapid Information on Patient Response to Therapies Targeting Metastasis

ANGLE plc Announces the Edith Cowan University, Perth, Australia, Has Published Results from A Study in Ovarian Cancer Patients Using the Parsortix® System

Price target increased to UK£1.80

ANGLE plc Announces the Publication of Research Undertaken by the World-Class Team At the University of Southern California Norris Cancer Center

ANGLE plc Provides Update on Lab Accreditation and Ovarian Study

Insufficient new directors

First half 2021 earnings released: UK£0.036 loss per share (vs UK£0.02 loss in 1H 2020)

ANGLE plc Announces Parsortix System Demonstrates Ability to Isolate CTCS for Downstream Gene Analysis Revealing Multiple Prognostic Biomarkers

Angle plc Announces That the Health Research Institute of Santiago

CFO, Finance Director exercised options to buy UK£524k worth of stock.

ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans

Founder exercised options and sold UK£1.0m worth of stock

Forecast to breakeven in 2025

ANGLE plc Announces Published Results of A New Study Undertaken in Non-Small Cell Lung Cancer